Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.

Cancer discovery - 3 Jun 2024

Kazansky Yaniv, Cameron Daniel, Mueller Helen S, Demarest Phillip, Zaffaroni Nadia, Arrighetti Noemi, Zuco Valentina, Kuwahara Yasumichi, Somwar Romel, Ladanyi Marc, Qu Rui, de Stanchina Elisa, Dela Cruz Filemon S, Kung Andrew L, Gounder Mrinal M, Kentsis Alex

Abstract excerpt

Epigenetic dependencies have become evident in many cancers. On the basis of antagonism between BAF/SWI-SNF and PRC2 in SMARCB1-deficient sarcomas, we recently completed the clinical trial of the EZH2 inhibitor tazemetostat. However, the principles of tumor response to epigenetic therapy in general, and tazemetostat in particular, remain unknown. Using functional genomics and diverse experimental models, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Biphenyl Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Enhancer of Zeste Homolog 2 Protein

Share to Epigenesis, Genetic

Share to Morpholines

Share to Pyridones

Share to SMARCB1 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 38315003
DOI: 10.1158/2159-8290.CD-23-0110
PMCID: PMC11147720

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.PMID 38315003Read ↗

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapySemantic proximity Read ↗

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasSemantic proximity Read ↗

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combinationSemantic proximity Read ↗

Targeting epigenetics in sarcomas through EZH2 inhibitionSemantic proximity Read ↗

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combinationSemantic proximity Read ↗

Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).Semantic proximity Read ↗

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read ↗

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma XenograftSemantic proximity Read ↗

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.Semantic proximity Read ↗

Mechanisms of action and resistance in histone methylation-targeted therapy.Semantic proximity Read ↗

Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers.Semantic proximity Read ↗

PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.